EORTC als Beispiel für Vernetzung und Zusammenarbeit in der Krebsforschung

Prof. Dr. med. Roger Stupp

European Organisation for Research and Treatment of

Cancer (EORTC), Brussels, Belgium &

Klinik für Oncology & Tumorzentrum

UniversitätsSpital Zürich

Dt: Die Europäische Organisation für Forschung und Therapie von Krebskrankheiten fr: L’organisation européenne de recherche et traitement du cancer

EORTC: The European Organisation for Research and Treatment of Cancer

2

Source: EORTC Annual Report 2012 -2013

EORTC aims to develop, conduct, coordinate,

and stimulate Pan-European translational and

clinical research to improve the standard of

cancer treatment for patients, and ultimately

increase survival and quality of life.

“”

Collaborations across many stakeholders

3

Yesterday Tomorrow

EORTC

Pharma &

Biotech

AcademiaCharitable

FundsEORTC

Pharma &

Biotech

Charitable

FundsAcademia

Gov’t

Bodies

Payers &

Health

Insurers

Patients

Technology

Companies

Regulators

& HTAs

?

?

Einige Tatsachen

• Krebs-Häufigkeit

• Krebs-Sterblichkeit

• Aus 10.000 chemischenSubstanzen entstehtlediglich ein Arzneimittel

Forschung

5

Drug DevelopmentPosition of EORTC

6

EORTC

• Private and not for profit organization created in 1962

• Main mission: promote and conduct researchto improve cancer care

• Core activity: conduct clinical trials

International

Multidisciplinary

Develop new treatments

Define new standards of care

Large academic trials

EUROPEAN ORGANIZATION FOR RESEARCH

AND TREATMENT OF CANCER (EORTC)

Henri Tagnon, Co-founder of EORTC

EORTC TODAY (2014)

• Network of more than 300 institutions from 29 different countries

• +/- 2,000 collaborators (clinicians, pathologists, researchers,....)

• About 6,000 patients are entered into EORTC trials each year (database of more than 150,000 patients)

• 50,000 patients being followed-up

• +/-30 trials open to patient entry

ACCRUAL OF PATIENTS IN EORTC STUDIES

(2000 – 2011) 71.905 PATIENTS

European Union: Austria: 810Belgium: 7.399Bulgaria: 49Cyprus: 73Czech Republic: 160Denmark: 529Estonia: 7Finland: 34France: 14.438Germany: 6.310Greece: 48Hungary: 210Italy: 6.553Latvia: 34Luxemburg: 9Malta: 20Poland: 1.082Portugal: 635Republic of Ireland: 90Romania: 20

Non-EU CountriesBosnia: 8Croatia: 352Macedonia: 6Norway: 454Serbia : 261Russia: 178Switzerland: 1.438Turkey: 631Ukraine: 4

Rest of the World: 3.941 patients

European Union (con’t):Slovak Republic: 451Slovenia: 310Spain: 2.867Sweden: 595The Netherlands: 15.279United Kingdom: 6.620

9

GIST: a very rare diseaseIncidence: 10-15/Mio CH: ca 75 neue Pat/Jahr

N Engl J Med 2001; 344:1052-1056

Eur J Cancer 2003, 39:2006-11

Lancet 2004; 364:1127-1134

EORTC 62024 (PI: P. Casalli)

EORTC 62024

EORTC 62062: GIST- Sx ± adj imatinib

(years)

0 1 2 3 4 5 6 7

0

10

20

30

40

50

60

70

80

90

100

O N Number of patients at risk : Treatment arm

160 453 344 309 278 207 95 28

121 454 429 410 359 250 105 21

Observation

Imatinib adjuvant

Relapse free survival

(years)

0 1 2 3 4 5 6 7

0

10

20

30

40

50

60

70

80

90

100

O N Number of patients at risk : Treatment arm

29 454 435 425 407 310 143 35

33 454 444 435 413 322 153 31

Observation

Imatinib adjuvant

Overall Survival

Relapse-free survival Overall survival

Treatment arm% at 5 Year(s)

(98.5% CI)

Observation99.10

(96.99, 99.73)

Imatinib Adj.99.78

(97.49, 99.98)

Treatment arm% at 3 Year(s)

(98.5% CI)

% at 5 Year(s)

(98.5% CI)

Observation65.83

(60.00, 71.03)

62.99

(56.93, 68.44)

Imatinib Adj.84.26

(79.48, 88.01)

69.40

(62.97, 74.94)

HR (adjusted for R0 vs R1, tumor site and risk group) : HR=0.58 (98.5%CI: 0.43-0.78)P<0.0001

Casalli et al. Proc ASCO 2013

EORTC: Numerous publicatations

Personalized MedicineFrequent Tumors become Rare

Harris et al. Discov Med 10(51):144-150, August 2010

Lung cancer is not

what it used to be

Adenocarcinoma

Pao, Nature Med 2012

Small cell lung cancer

Non-small cell lung cancer

CrizotinibXalkori®

VemurafenibZelboraf®

TrastuzumabHerceptin®

Gefitinib/ErlotinibIressa®/Tarceva®

CetuximabErbitux®

“Druggable” molecular abberations

Research Requires Infrastructure

• Preclinical • Clinical

! "#$%! "#$%&'(") %#*%#*+, *

! "&' %-. /& '#"01*

! ""' %*2"-"3"1. *%#*4 '#$%5 1*

( ) ) ) %4 . 3*60'#'6"0*"770'6") %#1*

( ) ! ( %*, 0%8$*6%&78) #9*

! ""**: ; ! <, *%#*-=. *5 . 3*

! "&) *78#6=*6"/$1*

Collaborations across many stakeholders

20

Yesterday Tomorrow

EORTC

Pharma &

Biotech

AcademiaCharitable

FundsEORTC

Pharma &

Biotech

Charitable

FundsAcademia

Gov’t

Bodies

Payers &

Health

Insurers

Patients

Technology

Companies

Regulators

& HTAs

?

?

The future of cancer therapy

EORTC PRESIDENTS 1962-2015

towards the future…

23